The Twelve Peptides Now Coming Off the Category 2 Restricted List Below is a clinical overview of the twelve peptides addressed by the April 2026 FDA action , organized by what patients typically ask them to do
consulting fees from AbbVie, BMS, Celltrion, Janssen, Novartis, Pfizer, and UCB
52 In a phase 1, randomized, double-blind placebo-controlled trial in individuals with obesity (without diabetes), this drug resulted in weight loss of 15% over 12 weeks at its highest dose of 420 mg (Table 2)
In one trial, subjects achieved up to a 20% decrease in body weight, making Tirzepatide one of the most effective anti-obesity peptides under investigation